BioPoint Inc

11/27/2025

11/25/2025

Delivered directly into the spinal fluid, Itvisma, a form of Zolgensma, can be used in patients of all ages (children, teens, and adults) to potentially stabilize or improve motor function. https://www.biopharmadive.com/news/fda-approve-novartis-sma-gene-therapy-itvisma-zolgensma-older-patients/806387/

Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor function.

11/20/2025

The company did not comment on Gottlieb's appointment, which coincides with its ongoing efforts to improve relations with federal regulators. https://www.biopharmadive.com/news/unitedhealth-adds-scott-gottlieb-board-of-directors/805924/

The company declined to comment on Gottlieb’s appointment, which comes as it works to improve its relationship with federal regulators.

11/19/2025

While a bipartisan report warned of China's growing control over the pharmaceutical supply chain, the U.S. industry is also seeing activity. Alkermes sweetened its bid for Avadel, and Moderna is investing $140 million in domestic drug production. https://www.biopharmadive.com/news/alkermes-avadel-china-biotech-moderna-lifordi-vanda/805824/

A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.

11/18/2025

Riding the momentum of promising data for a key cancer drug, Zymeworks is shifting its strategic focus, with its CEO aiming to deliver "more consistent value for shareholders" in the wake of potential blockbuster status. https://www.biopharmadive.com/news/zymeworks-data-royalty-restructuring-biotech-revenue-model/805726/

On the heels of a data readout suggesting one of its cancer drugs could become a future blockbuster, Zymeworks is adopting a new strategy its CEO says will create “more consistent value for shareholders.”

11/17/2025

A significant development in Duchenne muscular dystrophy treatment: Elevidys now has a boxed warning and is no longer an option for non-ambulatory patients. https://www.biopharmadive.com/news/fda-elevidys-nuvalent-alk-zymeworks-her2-nxera-layoffs/805607/

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

11/14/2025

In a multibillion-dollar deal, Merck is acquiring a drug that could provide a non-vaccine alternative for flu prevention, marking the second major buyout for the company this year. https://www.biopharmadive.com/news/merck-cidara-acquire-flu-antiviral-drug/805513/

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative to vaccines for flu prevention.

11/13/2025

The "plausible mechanism" pathway, proposed by Martin Makary and Vinay Prasad, leverages scientific understanding to expedite the creation of tailored therapies for individuals facing rare and severe diseases. https://www.biopharmadive.com/news/fda-plausible-mechanism-pathway-n-of-1-crispr/805235/

The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments custom-made for individuals with rare and serious diseases.

11/12/2025

Metagenomi is undergoing significant restructuring, with a 25% workforce reduction and leadership changes. In related news, Ovid has revealed a CEO succession plan. Meanwhile, investors reacted positively to developments at Cogent Biosciences and Galecto, driving up their share prices. https://www.biopharmadive.com/news/metagenomi-ovid-ceo-restructuring-cogent-galecto-anaptysbio-lyell/805172/

Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket. 

11/11/2025

The drug shows promise in treating both relapsing and primary progressive forms of the disease. However, some experts are debating whether Roche has sufficient data to support regulatory approval for the primary progressive form. https://www.biopharmadive.com/news/roche-ms-fenebrutinib-clinical-trial-results-data-relapsing-primary/805152/

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts question if Roche has collected enough data to ask for approval in the latter.

11/11/2025

We pause today to honor our Veterans—past and present—for their service, strength, and sacrifice. Your commitment inspires us every day.

11/10/2025

Lilly expands its genetic medicine portfolio, acquiring rights to a promising experimental treatment for a rare childhood blindness through a new alliance agreement. https://www.biopharmadive.com/news/eli-lilly-meiragtx-gene-therapy-ophthalmology-deal-lca4/805048/

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment for an ultra-rare form of childhood blindness.